Tsunenori Kondo

20PUBLICATIONS
28CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)French languageMolecular targetsRadiation therapyPanel data analysis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Oct 08, 2026
Prognostic impact of lenvatinib dose intensity in previously untreated patients with advanced renal cell carcinoma receiving lenvatinib plus pembrolizumab.

|Jul 10, 2026
Standardizing Upper Abdominal Fascial Terminology: A Transdisciplinary Expert Consensus From the Japanese Society for Endoscopic Surgery.

|May 07, 2026
Comparison of clinical outcomes of cabozantinib plus nivolumab and lenvatinib plus pembrolizumab in patients with metastatic renal cell carcinoma.

|Mar 02, 2026
Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma.

Hiroki Ishihara, Koichi Nishimura, Yuki Nemoto

|Jan 27, 2026
Non-Clear Cell Renal Cell Carcinoma Has an Immune-Cold Phenotype That Affects Response to Immune Checkpoint Inhibitors.

Hiroki Ishihara, Yu-Yu Liu, Riu Yamashita

|Nov 04, 2025
A Case of Complete Remission of Bilateral Upper Tract Carcinoma In Situ Following Retrograde Bacillus Calmette-Guérin (BCG) Instillation via Open-Ended Ureteral Catheters After Failure Using Double-J Stents.

Nanaka Katsurayama, Toshihide Horiuchi, Koichi Nishimura

Pageof 4

Frequent Collaborators

8 joint publications

Kazuhiko Yoshida

8 joint publications

Toshio Takagi

8 joint publications

Hiroki Ishihara

2 joint publications

Yudai Ishiyama